Irinotecan as maintenance therapy in high-risk hepatoblastoma

Muna Qayed, Christie Powell, Elaine R. Morgan, Maureen Haugen, Howard M. Katzenstein

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.

Original languageEnglish (US)
Pages (from-to)761-763
Number of pages3
JournalPediatric Blood and Cancer
Volume54
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

irinotecan
Hepatoblastoma
alpha-Fetoproteins
Vincristine
Therapeutics

Keywords

  • Hepatoblastoma
  • Irinotecan
  • Maintenance

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Qayed, Muna ; Powell, Christie ; Morgan, Elaine R. ; Haugen, Maureen ; Katzenstein, Howard M. / Irinotecan as maintenance therapy in high-risk hepatoblastoma. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 5. pp. 761-763.
@article{8dbf3715bf5041bda6c2f6c37aacd06a,
title = "Irinotecan as maintenance therapy in high-risk hepatoblastoma",
abstract = "Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.",
keywords = "Hepatoblastoma, Irinotecan, Maintenance",
author = "Muna Qayed and Christie Powell and Morgan, {Elaine R.} and Maureen Haugen and Katzenstein, {Howard M.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/pbc.22408",
language = "English (US)",
volume = "54",
pages = "761--763",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Qayed, M, Powell, C, Morgan, ER, Haugen, M & Katzenstein, HM 2010, 'Irinotecan as maintenance therapy in high-risk hepatoblastoma', Pediatric Blood and Cancer, vol. 54, no. 5, pp. 761-763. https://doi.org/10.1002/pbc.22408

Irinotecan as maintenance therapy in high-risk hepatoblastoma. / Qayed, Muna; Powell, Christie; Morgan, Elaine R.; Haugen, Maureen; Katzenstein, Howard M.

In: Pediatric Blood and Cancer, Vol. 54, No. 5, 01.05.2010, p. 761-763.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Irinotecan as maintenance therapy in high-risk hepatoblastoma

AU - Qayed, Muna

AU - Powell, Christie

AU - Morgan, Elaine R.

AU - Haugen, Maureen

AU - Katzenstein, Howard M.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.

AB - Children with high-risk hepatoblastoma (metastatic disease or a low alpha-fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1- to 2-year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high-risk and recurrent HB patients is warranted.

KW - Hepatoblastoma

KW - Irinotecan

KW - Maintenance

UR - http://www.scopus.com/inward/record.url?scp=77950463345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950463345&partnerID=8YFLogxK

U2 - 10.1002/pbc.22408

DO - 10.1002/pbc.22408

M3 - Article

C2 - 20063426

AN - SCOPUS:77950463345

VL - 54

SP - 761

EP - 763

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -